You searched for "MET"
The scent of Ethiopia: a personal story part 2
In May/June 2016 we featured a wonderful account of Zeeshan Aslam’s first trip with Urolink to the Hawassa Referral Hospital in Ethiopia (see here). One year on we are delighted that Zeeshan has once again taken the time to provide...Demanding cases or nightmares in uro-oncology? Jan/Feb 2022
When less is more: percutaneous biopsy and tumour seeding in papillary renal cell carcinoma Renal cell carcinoma (RCC) accounted for 2.2% of new cancer diagnoses worldwide in 2018 with over 400,000 new cases and 175,098 deaths [1]. The majority of...Prostate artery embolisation
Introduction Benign prostatic hyperplasia (BPH), a common condition associated with ageing, affects 50% of those between the ages of 50 and 60 years, and as many as 90% of those older than 80 years. BPH is characterised by unregulated, benign...Urologist in a chocolate box: Felix Guyon
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). It is not often we get to say someone in urology has something...Spencer Wells
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I wrote about some well-used eponyms seen in the...USANZ Trainee Week 2024
It is our pleasure to report on our attendance at the Urological Society of Australia and New Zealand (USANZ) Trainee Week in Brisbane at the end of 2024. Firstly, we would like to thank The Urology Foundation, BSoT and BAUS...Preparing for the FRCS (Urol) viva
Ping! You look down to your phone and you have just received an email saying, “Congratulations, you have now successfully completed The Joint Committee on Intercollegiate Examinations section 1 of the Fellowship of the Royal College of Surgeons (Urol) exam.”...Urinary biomarkers for surveillance of non-muscle invasive bladder cancer
Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...TUF Warriors – joining the fundraising fight
What is the TUF Warrior programme? The Urology Foundation (TUF) Warrior programme is designed to support core trainees, clinical fellows and foundation doctors interested in urology. It creates opportunities to develop extracurricular interests, connect with patients, boost applications for specialty...Recent developments in bladder cancer – MIBC
This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...
